Boothbay Fund Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Boothbay Fund Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-16,000	Closed	-$113K	–	2206
2021 Q1	$113K	Buy	+16,000	New	+$115K	﹤0.01%	1462
2020 Q3	–	Sell	-22,495	Closed	-$117K	–	1293
2020 Q2	$117K	Buy	+22,495	New	+$99.9K	0.01%	865
2017 Q3	–	Sell	-28,201	Closed	-$680K	–	814
2017 Q2	$680K	Sell	28,201 -19,265	-41%	-$426K	0.14%	157
2017 Q1	$914K	Buy	+47,466	New	+$748K	0.17%	144

Other funds holding PRTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boothbay Fund Management's PRTK Position: Q2 2021 in Review

Boothbay Fund Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2021, closing a stake of 16,000 shares — an estimated $113K sold.

Boothbay Fund Management first reported a position in PRTK in Q1 2017 and held it in 4 quarters. The position peaked at $914K in Q1 2017. 116 funds tracked by Wall St. Rank hold PRTK as of Q2 2021.

Boothbay Fund Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Boothbay Fund Management sold 16,000 Paratek Pharmaceuticals, Inc. shares in Q2 2021, an estimated $113K.
Boothbay Fund Management first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2017 and held it in 4 quarters.
Boothbay Fund Management's Paratek Pharmaceuticals, Inc. position peaked at $914K in Q1 2017.
116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2021.

Based on Boothbay Fund Management's 13F filing for Q2 2021, filed 16 Aug 2021.